Clemizole hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to GlobalData, Phase II drugs for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Clemizole hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Clemizole hydrochloride overview

Clemizole HCL (EPX-100) is under development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and otahara syndrome. The drug candidate acts by targeting 5-hydroxytryptamine receptor (serotonin receptor). The drug candidate administered orally. It is developed based on proprietary phenotype-based zebrafish drug screening platform.

For a complete picture of Clemizole hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.